Contrasting Predictive Oncology (NASDAQ:POAI) & Opsens (OTCMKTS:OPSSF)

Opsens (OTCMKTS:OPSSF) and Predictive Oncology (NASDAQ:POAI) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.

Valuation & Earnings

This table compares Opsens and Predictive Oncology’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opsens	N/A	N/A	N/A	N/A	N/A
Predictive Oncology	$1.55 million	8.09	-$25.74 million	($4.84)	-0.64

Opsens has higher earnings, but lower revenue than Predictive Oncology.

Profitability

This table compares Opsens and Predictive Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opsens	N/A	N/A	N/A
Predictive Oncology	-1,246.52%	-90.72%	-73.16%

Institutional and Insider Ownership

6.0% of Predictive Oncology shares are owned by institutional investors. 2.3% of Predictive Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Opsens and Predictive Oncology, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opsens	0	0	1	0	3.00
Predictive Oncology	0	0	0	0	N/A

Opsens currently has a consensus price target of $2.50, suggesting a potential upside of 83.82%. Given Opsens’ higher probable upside, research analysts plainly believe Opsens is more favorable than Predictive Oncology.

Summary

Opsens beats Predictive Oncology on 5 of the 8 factors compared between the two stocks.

About Opsens

Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for cardiovascular interventions. The company operates in two segments, Medical and Industrial. The company offers fiber optic temperature, pressure, strain, and displacement sensor products; and fiber optic extensometer and signal conditioner/OEM boards. It serves energy, aerospace and defense, industrial and laboratory, smart structure health monitoring, geotechnical, and power electronics and semiconductors markets. The company sells its products through a network of distributors and direct sales force in the United States, Japan, Canada, and internationally. Opsens Inc. was formerly known as Capital DCB inc. and changed its name to OpSens Inc. in October 2006. The company was founded in 2003 and is headquartered in Québec, Canada.

About Predictive Oncology

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.